Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Sohn

Internal Medicine Arlington Heights, IL Medical Doctor

NPI 1972723625 CMS profile 316194

637 E Golf Rd, Suite 208, Arlington Heights, IL 60005

Open in the dashboard

General payments

$20,661

519 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Sohn of Arlington Heights, IL is reported in the CMS Open Payments database as having received $20,661 across 519 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,427 86
2024 General $3,459 83
2023 General $2,698 66
2022 General $2,795 70
2021 General $2,830 76
2020 General $1,636 67
2019 General $2,816 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Sohn
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kevin Sohn were reported at $4,427. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kevin Sohn Internal Medicine median Middle half National median
2019 $2,816 $159 $48–$570 $163
2020 $1,636 $119 $33–$402 $114
2021 $2,830 $135 $37–$521 $132
2022 $2,795 $141 $42–$496 $149
2023 $2,698 $149 $45–$519 $160
2024 $3,459 $154 $47–$537 $164
2025 $4,427 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $3,586 63 payments
  2. Amgen Inc. $3,062 86 payments
  3. Novo Nordisk Inc $2,007 57 payments
  4. Lilly USA, LLC $1,966 60 payments
  5. Abbott Laboratories $1,952 18 payments
  6. AstraZeneca Pharmaceuticals LP $1,360 37 payments
  7. Amarin Pharma Inc. $1,257 38 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $712 18 payments
  9. Corcept Therapeutics $697 15 payments
  10. Pfizer Inc. $492 17 payments
  11. Other $3,569 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,314 510 payments
  2. Gift $226 4 payments
  3. Education $120 5 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $2,020 41 payments
  2. FreeStyle Libre 3 $1,479 14 payments
  3. JARDIANCE Diabetes $1,380 20 payments
  4. EVENITY $1,375 42 payments
  5. Ozempic $1,295 45 payments
  6. JARDIANCE Diabetes $1,004 44 payments
  7. RYBELSUS $871 35 payments
  8. MOUNJARO $829 14 payments
  9. FARXIGA $781 28 payments
  10. Vascepa $763 14 payments
  11. Other $13,131 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,103

Median for Internal Medicine: 777

Drug cost

$153,884

Median for Internal Medicine: $73,373

Branded share of claims

14.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 43 $65,254
Ozempic Semaglutide Brand 13 $25,174
Xarelto Rivaroxaban Brand 11 $14,015
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 29 $9,086
Synjardy Xr Empagliflozin/Metformin Hcl Brand 12 $8,218
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 26 $8,089
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 11 $2,345
Amlodipine Besylate Generic 188 $2,053
Atorvastatin Calcium Generic 231 $2,007
Losartan Potassium Generic 176 $1,621

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$68,124

Of which drugs: $106

Medicare patients

147

Average age 75

Services billed

1,502

73 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 34%
Osteoporosis 24%
Arthritis 21%
Chronic kidney disease 20%
Ischemic heart disease 19%
COPD 11%
Atrial fibrillation 7%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution , 1000 cc J7030 Office 25 28 $56
Injection, fentanyl citrate, 0.1 mg J3010 Office 22 46 $31
Injection, propofol, 10 mg J2704 Office 18 138 $11
Injection, midazolam hydrochloride, per 1 mg J2250 Office 20 72 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$737 43 —
MOUNJARO
$304 — —
FARXIGA
$229 — —
VOQUEZNA
$202 — —
Korlym
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

519 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record